Pharmacokinetics of Rilpivirine and 24-Week Outcomes after Switching from Efavirenz in Virologically Suppressed HIV-1-Infected Adolescents

Background Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor drug, could be a favourable drug for maintenance therapy in HIV-infected adolescents because it has few long-term side effects. However, data among adolescents switching from efavirenz (EFV) to RPV are limited. This study investigated the pharmacokinetics (PK), safety and efficacy of RPV in virologically suppressed HIV-1-infected adolescents after switching from EFV. Methods Adolescents aged 12–18 years on EFV-based antiretroviral therapy (ART) were switched from EFV to RPV (25 mg, once daily). Intensive 24-h blood samplings at 0 (pre-dose), 1, 2, 4, 5, 6, 9, 12 and 24 h were performed 4 weeks after switching. PK parameters were calculated using a non-compartmental method and compared with published data from the PAINT and pooled ECHO/THRIVE substudies. HIV RNA level was measured at weeks 12 and 24. Biochemical profiles were measured at baseline and week 24. Results From January to June 2016, 20 adolescents (12 male) were enrolled. Median (IQR) age was 16 (15–17) years and weight was 49 (42–59) kg. Mean (sd) AUC24 h, C24 h and Cmax of RPV were 2,041 (745) ng•h/ml, 69 (29) ng/ml and 143 (65) ng/ml, respectively. Median (IQR) Tmax was 5 (2–9) h. Four adolescents had C24 h <40 ng/ml. All PK parameters were comparable with published data. All adolescents remained virologically suppressed at week 24. Significant decreases in fasting total cholesterol, triglyceride and low-density lipoprotein were observed (P-value <0.05). Conclusions Virologically suppressed HIV-infected adolescents had adequate RPV exposure and remained virologically suppressed after switching from EFV. RPV can be used as long-term maintenance ART in HIV-infected adolescents.

[1]  T. Bunupuradah,et al.  Rilpivirine as a Treatment for HIV-infected Antiretroviral-naïve Adolescents: Week 48 Safety, Efficacy, Virology and Pharmacokinetics , 2016, The Pediatric infectious disease journal.

[2]  T. Buclin,et al.  Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals , 2016, Antimicrobial Agents and Chemotherapy.

[3]  C. Leen,et al.  British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2015 , 2016, HIV medicine.

[4]  P. Mootsikapun,et al.  Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia , 2016, HIV clinical trials.

[5]  J. van Lunzen,et al.  Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study , 2016, AIDS.

[6]  D. Haas,et al.  Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations , 2016, Medicine.

[7]  A. Farr,et al.  No Evidence of an Association Between Efavirenz Exposure and Suicidality Among HIV Patients Initiating Antiretroviral Therapy in a Retrospective Cohort Study of Real World Data , 2016, Medicine.

[8]  F. Dabis,et al.  Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012–2014 , 2015, Open forum infectious diseases.

[9]  P. Sax,et al.  Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide , 2014, Annals of Internal Medicine.

[10]  K. White,et al.  Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults , 2014, AIDS.

[11]  K. White,et al.  Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis. , 2014, AIDS patient care and STDs.

[12]  C. Orkin,et al.  Week 96 analysis of rilpivirine or efavirenz in HIV‐1‐infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double‐blind trials , 2014, HIV medicine.

[13]  C. Leen,et al.  British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.) , 2014, HIV medicine.

[14]  K. White,et al.  Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens , 2013, HIV clinical trials.

[15]  H. Crauwels,et al.  Impact of Food and Different Meal Types on the Pharmacokinetics of Rilpivirine , 2013, Journal of clinical pharmacology.

[16]  W. Short,et al.  Effect of gender and race on the week 48 findings in treatment‐naïve, HIV‐1‐infected patients enrolled in the randomized, phase III trials ECHO and THRIVE , 2012, HIV medicine.

[17]  B. Clotet,et al.  Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients: Pooled Results From the Phase 3 Double-Blind Randomized ECHO and THRIVE Trials , 2012, Journal of acquired immune deficiency syndromes.

[18]  H. Crauwels,et al.  Pharmacokinetic Parameters of Once-Daily Rilpivirine following Administration of Efavirenz in Healthy Subjects , 2012, Antiviral therapy.

[19]  H. Goforth,et al.  A Systematic Review of the Psychiatric Side-Effects of Efavirenz , 2011, AIDS and Behavior.

[20]  A. Wierzbicki,et al.  Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study , 2010, International journal of clinical practice.

[21]  D. Clifford,et al.  Long-Term Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals (ACTG 5097s) , 2009, HIV clinical trials.